Evidence map›Paper›PMID 32865517›Full record

ArticleThe Journal of clinical investigation2020

Human NK cell deficiency as a result of biallelic mutations in MCM10.

Emily M Mace, Silke Paust, Matilde I Conte, Ryan M Baxley, Megan M Schmit, Sagar L Patil, Nicole C Guilz, Malini Mukherjee, Ashley E Pezzi, Jolanta Chmielowiec and 18 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. The genetic basis of human height.Nature reviews. Genetics · 2025
    Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Inborn Errors of Immunity and Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 10 institutions in 4 countries.

Emily M MaceDepartment of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.
Silke PaustDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, California, USA.
Matilde I ConteDepartment of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.
Ryan M BaxleyDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Megan M SchmitDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Sagar L PatilDepartment of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.
Nicole C GuilzDepartment of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.
Malini MukherjeeCenter for Human Immunobiology, Texas Children's Hospital, Houston, Texas, USA.
Ashley E PezziCenter for Human Immunobiology, Texas Children's Hospital, Houston, Texas, USA.
Jolanta ChmielowiecCenter for Cell and Gene Therapy, and.
Swetha TatineniDepartment of Pediatrics.
Ivan K ChinnDepartment of Pediatrics.
Zeynep Coban AkdemirDepartment of Molecular and Human Genetics and.
Shalini N JhangianiDepartment of Molecular and Human Genetics and.
Donna M MuznyDepartment of Molecular and Human Genetics and.
Asbjørg Stray-PedersenNorwegian National Unit for Newborn Screening, Division of Pediatric and Adolescent Medicine, Oslo, Norway.
Rachel E BradleyImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, Wales.
Mo MoodyImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, Wales.
Philip P ConnorImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, Wales.
Adrian G HeapsDepartment of Virology and Immunology, North Cumbria University Hospitals, Carlisle, United Kingdom.
Colin StewardDepartment of Paediatric Haematology, Oncology and Bone Marrow Transplantation, Bristol Royal Hospital for Children, Bristol, United Kingdom.
Pinaki P BanerjeeCenter for Human Immunobiology, Texas Children's Hospital, Houston, Texas, USA.
Richard A GibbsDepartment of Molecular and Human Genetics and.
Malgorzata BorowiakCenter for Cell and Gene Therapy, and.
James R LupskiDepartment of Pediatrics.
Stephen JollesImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, Wales.
Anja K BielinskyDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Jordan S OrangeDepartment of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.
Baylor College of Medicine · USColumbia University · USPediatrics and Genetics · USUniversity Hospital of Wales · GBUniversity of Minnesota · USBristol Royal Hospital for Children · GBCenter for Child and Adolescent Mental Health, Eastern and Southern Norway · NOScripps Research Institute · USTexas Medical Center · USUniversity of Cumbria · GB

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Baylor-Johns Hopkins Center for Mendelian GeneticsUM1HG006542 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 2016 to 2020
$14.5M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
GENETIC, IMMUNOLOGIC AND MECHANISTIC BASIS OF HUMAN NK CELL DEFICIENCYR01AI120989 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ORANGE, JORDAN SCOTT · 2016 to 2025
$7.7M
NUTRITIONT32DK007647 · NIDDK · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anthony W Ferrante, Lori M Zeltser · 1990 to 2026
$7.4M
STRUCTURAL VARIATION IN NEUROLOGICAL DISEASER35NS105078 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI LUPSKI, JAMES R. · 2018 to 2025
$6.0M
Understanding the biological function of Mcm10 in yeastR01GM074917 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BIELINSKY, ANJA-KATRIN · 2005 to 2019
$3.7M
NRSA Training CoreTL1TR002493 · NCATS · UNIVERSITY OF MINNESOTA · PI FULKERSON, JAYNE ALLYN · 2018 to 2022
$3.1M
The role of DNA damage tolerance pathways in human cellsR01GM134681 · NIGMS · UNIVERSITY OF VIRGINIA · PI George Lucian Moldovan, Claudia M Nicolae · 2019 to 2026
$3.0M
DETERMINING THE ROLE OF THE REPLICATIVE HELICASE IN HUMAN NK CELL DEVELOPMENTR01AI137275 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MACE, EMILY MARGARET · 2018 to 2022
$1.9M
NCATS NIH HHS TL1 TR002493NCATS NIH HHS UL1 TR002494NCI NIH HHS T32 CA009138NHGRI NIH HHS UM1 HG006542NIAID NIH HHS R01 AI120989NIAID NIH HHS R01 AI137275NIDDK NIH HHS T32 DK007647NIGMS NIH HHS R01 GM074917NIGMS NIH HHS R01 GM134681NIGMS NIH HHS T32 GM008244NINDS NIH HHS R35 NS105078
6 · The paper itself

Abstract

Human natural killer cell deficiency (NKD) arises from inborn errors of immunity that lead to impaired NK cell development, function, or both. Through the understanding of the biological perturbations in individuals with NKD, requirements for the generation of terminally mature functional innate effector cells can be elucidated. Here, we report a cause of NKD resulting from compound heterozygous mutations in minichromosomal maintenance complex member 10 (MCM10) that impaired NK cell maturation in a child with fatal susceptibility to CMV. MCM10 has not been previously associated with monogenic disease and plays a critical role in the activation and function of the eukaryotic DNA replisome. Through evaluation of patient primary fibroblasts, modeling patient mutations in fibroblast cell lines, and MCM10 knockdown in human NK cell lines, we have shown that loss of MCM10 function leads to impaired cell cycle progression and induction of DNA damage-response pathways. By modeling MCM10 deficiency in primary NK cell precursors, including patient-derived induced pluripotent stem cells, we further demonstrated that MCM10 is required for NK cell terminal maturation and acquisition of immunological system function. Together, these data define MCM10 as an NKD gene and provide biological insight into the requirement for the DNA replisome in human NK cell maturation and function.

Indexed as

MutationAllelesCell Cycle CheckpointsCell DifferentiationCell LineCodon, NonsenseDNA DamageFatal OutcomeFemaleGene Knockdown TechniquesHeterozygoteHumansInduced Pluripotent Stem CellsInfantKiller Cells, NaturalMaleCodon, NonsenseMCM10 protein, humanMinichromosome Maintenance ProteinsGenetic diseasesImmunologyNK cells

Identifiers

PMID32865517
PMCPMC7524476
OpenAlexW3082045817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.